You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,241,920


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,241,920
Title:Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression
Abstract: The present invention is directed to methods of inhibiting cancer cell proliferation, differentiation and/or survival. These methods involve the administration of Fbw7 E3 ligase inhibitors to inhibit c-Myc ubiquitination in cancerous cell populations, such as leukemic initiating cell populations, that are responsible for disease initiation and progression.
Inventor(s): Aifantis; Iannis (Brooklyn, NY), Reavie; Linsey (Binningen, CH), Buckley; Shannon (New York, NY)
Assignee: NEW YORK UNIVERSITY (New York, NY)
Application Number:14/354,822
Patent Claims:1. A method of inhibiting proliferation of leukemia cells said method comprising: administering to a population of leukemia cells a Fbw7 inhibitor, wherein the Fbw7 inhibitor is 1-(2-carboxynaphth-lyl)-2-naphthoic acid (SCF-12), in an amount.

2. The method of claim 1, wherein the population of leukemic cells are selected from the group consisting of chronic myeloid leukemia cells, acute myeloid leukemia cells, and B-cell acute lymphoblastic leukemia cells.

3. The method of claim 1, wherein the population of leukemia cells comprise a population of leukemic initiating cells.

4. The method of claim 3, wherein the population of leukemic initiating cells comprises a population of BCR-ABL.sup.+CD34.sup.+CD38.sup.- cells.

5. The method of claim 1, wherein said administering is in vivo.

6. The method according to claim 1, wherein said administering is carried out in combination with another leukemia therapeutic.

7. The method according to claim 6, wherein the leukemia therapeutic comprises a tyrosine kinase inhibitor.

8. The method according to claim 7, wherein the tyrosine kinase inhibitor is selected from the group consisting of imatinib mesylate, nilotinib, and dasatinib.

9. The method according to claim 6, wherein the leukemia therapeutic is selected from the group consisting of a chemotherapeutic agent, radiation, an anti-angiogenic agent, an immune-enhancing agent, and combinations thereof.

10. The method according to claim 9, wherein the leukemia therapeutic is a chemotherapeutic agent selected from the group consisting of cytarabine, cyclophosphamide, vincristine, prednisone, daunorubicin, PEG asparaginase, methotrexate, and leucovorin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.